课题基金 / 基金详情

Trial to Evaluate Anti-fibrinolytic Therapy in Thrombocytopenia (TREATT)

Trial to Evaluate Anti-fibrinolytic Therapy in Thrombocytopenia (TREATT)
评估血小板减少症抗纤溶疗法的试验 (TREATT)
批准号:
nhmrc : 1085062
负责人:
A/Pr David Westerman
金额:
$70.51万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2015
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2015-01-01 至 2019-12-31

项目摘要

项目成果

A/Pr David Westerman的其他基金

相似基金

相关文献

中文摘要
翻译
血液恶性肿瘤患者通常因疾病或治疗而导致血小板计数降低。这可能与出血有关,有时可能是严重的或致命的。在澳大利亚,近三分之二的血小板输注是在这种情况下进行的,以防止出血,但许多人仍然会发生出血。这项研究询问氨甲环酸是否可以安全有效地减少出血,如果可以,减少出血是否会导致血小板输注减少?
英文摘要
Patients with haematologic malignancies often have low platelet counts from their disease or treatment. This can be associated with bleeding, which can sometimes be serious or fatal. Nearly 2/3 of all platelet transfusions in Australia are given in this setting to try to prevent bleeding but many people still experience bleeding. This study asks whether tranexamic acid can safely & effectively reduce bleeding and if it does, does reduced bleeding lead to reduction in platelet transfusions?
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Trial to Evaluate Anti-fibrinolytic Therapy in Thrombocytopenia (TREATT)
  • 批准号:
    nhmrc : GNT1085062
  • 项目类别:
    Project Grants
  • 资助金额:
    $101.26万
  • 财政年份:
    2015
  • 负责人:
    A/Pr David Westerman
  • 依托单位:
海外基金